A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients - ND

BOEHRINGER ING.0 个研究点开始时间: 2008年7月8日最近更新: 2013年7月22日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•-Male and female patients aged >= 18 years. -Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural effusion) or Stage IV and histopathological classification of adeno- or bronchoalveolar carcinoma (BAC). -Increased EGFR gene copy number assessed by FISH analysis. After signed informed consent, positive result to EGFR FISH determination is mandatory to proceed to other screening assessments. -At least one tumour lesion that can accurately be measured by computed tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to be recorded as >=20 mm using conventional techniques or >=10 mm with spiral CT scan. -Prior chemotherapy: o 1st line patients (40 in total): no previous exposure to chemotherapy for NSCLC. Patients who received adjuvant chemotherapy and at least 12 months has elapsed since last administration of treatment will be considered 1st line. (2nd line patients (30 in total): relapse after one line of systemic treatment.In patients treated with adjuvant chemotherapy, if less than 12 months has elapsed since the last administration of treatment, patients are considered 2nd line ones, as adjuvant chemotherapy must be considered a line of treatment). -Life expectancy of at least three (3) months. -Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0, 1 or 2. -Written informed consent that is consistent with ICH-GCP guidelines
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•-More than two (2) prior cytotoxic chemotherapy treatment regimens for NSCLC, included adjuvant chemotherapy if relapse occurred less than 12 months before. -Previous treatment with erlotinib (Tarceva), gefitinib (Iressa) or any other EGFR inhibiting small molecule or antibody. -Active brain metastases (stable <4 weeks, symptomatic, requiring treatment with anticonvulsants, or leptomeningeal disease). Dexamethasone therapy will be allowed if administered as a stable dose for at least one month before randomization. -Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks before first drug administration. -Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn?s disease, malabsorption, or CTCAE Grade >2 diarrhea of any etiology at baseline. -Patients who have any other life-threatening illness or organ system dysfunction which, in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug. -Other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer and in situ cervical cancer). -Radiotherapy within the past 2 weeks prior to treatment with the trial drug. -Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents). -Patients with known HIV, active hepatitis B or active hepatitis C. -Known or suspected active drug or alcohol abuse. -Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial. -Pregnancy or breast feeding. -Patients unable to comply with the protocol. -History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3. -Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or Echocardiogram. -Absolute neutrophil count (ANC) less than 1500/mm**3. -Platelet count less than 100 000 / mm**3. -Bilirubin greater than 1.5 mg / dl (>26 micro mol / L, SI unit equivalent). Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal). -Serum creatinine greater than 1.5 times of the upper normal limit

研究者

发起方

BOEHRINGER ING.

相似试验

进行中（未招募）

1 期

A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patients - BIBW 2992 in demographically / genotypically NSCLCpatients with non-small cell lung cancer in stage IIB / IV

EUCTR2008-001546-67-BESCS Boehringer Ingelheim Comm.V40

进行中（未招募）

1 期

A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients.

EUCTR2008-007097-38-BESCS Boehringer Ingelheim Comm.V146

进行中（未招募）

1 期

EUCTR2008-007097-38-FRBoehringer-Ingelheim France146

已完成

3 期

Phase IIIB randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator's choise of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatmentnon-small-cell lungcancer/ lungcancer10038666

NL-OMON36544Boehringer Ingelheim40

招募中

2 期

Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

CTRI/2011/07/001915Boehringer Ingelheim Pharmaceuticals120